Inflammatory Bowel Disease Drivers Revealed in Human Organ Chips

Alican Özkan[1], Gwenn Merry[1], David B. Chou[1,2], Ryan R. Posey[1], Anna Stejskalova[1], Karina

Calderon[1], Megan Sperry[1], Viktor Horvath[1,10], Lorenzo E. Ferri[3,4], Emanuela Carlotti[5], Stuart A.

C. McDonald[5], Douglas J. Winton[6], Rocco Riccardi[7], Lilianna Bordeianou[7], Sean Hall[1,11], Girija

Goyal[1], Donald E. Ingber[1,8,9,*]

[1] Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA
[2] Department of Pathology, Massachusetts General Hospital, Boston, MA
[3] Thoracic and Upper GI Cancer Research Laboratories, Research Institute of McGill University
Health Centre, Montreal, QC, Canada
[4] Department of Experimental Surgery and Department of Surgery, McGill University, Montreal,
QC, Canada
[5] Clonal Dynamics in Epithelia Laboratory, Queen Mary University of London, London, United
Kingdom
[6] Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Cambridge, United Kingdom
[7] Department of Surgery, Massachusetts General Hospital, Boston, MA
[8] Vascular Biology Program and Department of Surgery, Boston Children's Hospital and
Harvard Medical School, Boston, MA
[9] Harvard John A. Paulson School of Engineering and Applied Sciences, Cambridge, MA
[10] Current address: Entact Bio, Watertown, MA
[11] Current address: Iovance Therapeutics, Tampa, FL

*Address correspondence to: Donald E. Ingber, MD,PhD
25   201 Brookline Ave., Suite 401, Boston MA, 02215, USA
26   em: don.ingber@wyss.harvard.edu

28   Keywords: Organ-on-a-chip, Ulcerative Colitis, Crohn's Disease, Inflammation, Cancer,
29   Carcinogenesis, Epithelial-Stromal Interactions, Women's health

Abstract

Inflammatory bowel disease (IBD) patients exhibit compromised intestinal barrier function and decreased mucus accumulation, as well as increased inflammation, fibrosis, and cancer risk, with symptoms often being exacerbated in women during pregnancy. Here, we show that these IBD hallmarks can be replicated using human Organ Chips lined by IBD patient-derived colon epithelial cells interfaced with matched fibroblasts cultured under flow. Use of heterotypic tissue recombinants revealed that IBD fibroblasts are the primary drivers of multiple IBD symptoms. Inflammation and fibrosis are accentuated by peristalsis-like motions in IBD Chips and when exposed to pregnancy-associated hormones in female IBD Chips. Carcinogen exposure also increases inflammation, gene mutations, and chromosome duplication in IBD Chips, but not in Healthy Chips. These data enabled by human Organ Chip technology suggest that the intestinal stroma and peristalsis-associated mechanical deformations play a key role in driving inflammation and disease progression in male and female IBD patients.

____

Main

Inflammation of the intestinal mucosa, including enhanced production of inflammatory cytokines and tissue infiltration with immune cells, along with increased barrier permeability, thinning of the protective mucus layer, and fibrosis are central hallmarks of inflammatory bowel diseases (IBD), such as Crohn's disease (Crohn's) and ulcerative colitis (UC). These alterations lead to significant digestive issues and an increased risk of developing colorectal cancer[1]. IBD symptoms also can be more prominent in women[2] and they have to control their symptoms before pregnancy because exacerbations increase the risk of preterm birth[3]. Most IBD treatments target immune cells rather than intestinal tissues, and treatment efficacy is variable among patients[4]. However, interactions between epithelia and underlying stroma also may

contribute to inflammation as well as cancer progression[5]. For example, the presence of a

subset of fibroblasts that recruit immune cells to the intestinal stem cell niche is associated with

poor prognosis in patients with colorectal cancer[6]. Inflamed epithelial cells also can undergo an

epithelial-to-mesenchymal transition and increase deposition of extracellular matrix (ECM)

resulting in intestinal fibrosis that leads to complications, such as bowel stiffening and restriction

of lumenal fluid flow, which further exacerbate digestive problems in IBD patients [7,8]. Thus, there

is a need to gain greater insight into how epithelial-stromal interactions, peristalsis, and fluid

flow influence IBD development in both male and female patients. However, animal IBD models

and in vitro studies with human intestinal cell lines lack direct relevance to the human disease[9],

and human intestinal organoids cannot be used to address these questions because they lack

an epithelial-stromal interface, mucosal barrier, fluid flow, peristalsis motions, and immune cells,

which are critical organ-level features required to address these questions.

Here, we leveraged human organ-on-a-chip (Organ Chip) microfluidic culture technology

that recreates tissue-tissue interfaces and a physiologically relevant intestinal microenvironment

including dynamic fluid flow, peristalsis-like mechanical deformations, and circulating immune

cells to confront this challenge[10,11]. Colon Chips lined by human organoid-derived colonic

epithelium cultured under dynamic fluid flow have been successfully used in the past to study

mucus layer accumulation and physiology[12,13] as well as to identify microbiome metabolites that

influence host response to bacterial infections[14]. In this study, we isolated epithelium and

stromal-derived fibroblasts from the same regions of colon from healthy or IBD patients and

used them to create Colon Chips that contained an epithelial-fibroblast interface. We also

created heterotypic tissue recombinant chips, measured the effects of applying peristalsis-like

motions and flowing immune cells through the stromal channel, and studied the effects of

female hormones on the IBD state, in addition to modeling cancer progression exposing the

Colon Chips to carcinogens in vitro.

Results

Establishment of Human Healthy and IBD Colon Chips

Patient-specific epithelial organoids and stromal fibroblasts were isolated from surgical biopsies of the sigmoid colon of healthy and IBD patients with Crohn's or UC (**Extended Data Fig. 1A** and **Supplementary Information**) and the organoids were expanded in Matrigel cultures while the fibroblasts were cultured on plastic dishes (**Extended Data Fig. 1B**). To build the human Colon Chips, the primary colon epithelial cells and fibroblasts were respectively seeded on the top and bottom surfaces of a porous ECM-coated membrane that separates two parallel channels within a commercially available microfluidic Organ Chip (**Fig. 1A**). The cells were allowed to adhere under static conditions for 1 day before flow was initiated. A continuous epithelial monolayer with undulating crypt-like structures formed by 11 days in Healthy Chips when viewed from above (**Fig. 1B,C)** or in cross sections (**Fig. 1D,E**). The epithelium became progressively obscured by dense opaque deposits from day 3 to 7, which completely filled the upper channel by day 11 (**Fig. 1C**). These opaque materials have been shown to be composed of mucus with similar composition, thickness, and bilayer structure as seen in human colonic mucus in vivo [12,13]. Similar chips lined with colonic epithelium and fibroblasts from Crohn's or UC patient samples also formed hill and crypt-like structures, but significantly but significantly less mucus accumulated on top of the epithelium, particularly in the UC chips (**Fig. 1C** and **Extended Data Fig. 1C**) and the heights of the intestinal epithelium were significantly reduced as well (**Fig. 1E**). Epithelial cells within both Healthy and IBD Chips also expressed colon-specific cytokeratin 20 along their apical borders, while the basal stem cell marker SOX9 primarily appeared in their nuclei at the cell base (**Fig. 1F**), which is a hallmark of colon crypts in vivo [23].

Past work has shown that there is a subset of stromal fibroblasts in IBD patients that have higher levels of expression of oncostatin M receptor (OSMR) and podoplanin (PDPN)[6], which appear to play a significant role in inflammation, fibrosis, and cancer[24]. Indeed, when we

carried out flow cytometric analysis after removing stromal cells from the chips, we found that

PDPN expression was significantly higher in IBD fibroblasts that expressed high OSMR levels

(**Extended Data Fig. 2A,B**) and that fibroblasts in IBD Chips lined by cells from both Crohn's

and UC patients secreted more inflammatory cytokines (e.g, IL6, IL8, MCP-1) from the basal

channel than those in Healthy Chips (**Fig. 1G**). We also found that fibroblasts in IBD Chips

established using both Crohn's and UC patients samples express higher vimentin and α-SMA

than healthy controls (**Extended Data Fig. 2C,D**), as previously observed in IBD mice models

induced by treatment with DSS or IL10 knock out[25].

Transcriptomic analysis of epithelial cells and fibroblasts individually within Healthy

versus IBD Chips revealed that genes which were found to be overexpressed in Crohn's and

UC (e.g., ADA2, APOBEC3B, GSPT2, CD40, ACAN, HLA-DQB1) epithelium on-chip were also

expressed at higher levels compared to healthy epithelium (**Extended Data Fig. 3A,B**). In

addition, genes suppressed in IBD patient tissues in vivo (e.g., MUC5B, FDFT1 in Crohn's and

SOD3, SMIM32, APOBR in UC [26–30]) were expressed at lower levels by epithelium in both

Crohn's and UC IBD Chips.

When stromal cells cultured in IBD Chips were similarly analyzed, they displayed

expression of IBD-relevant genes with Crohn's fibroblasts overexpressing ITGA7, FXD1, HGF,

FZD7, NKX2-3, LOXL3 relative to healthy fibroblasts, while high levels of IKBIP, NKX2-3, ADA2,

ECM2, NDN, SLC22A17 were seen in UC fibroblasts **(Extended Data. Fig. 3C,D)**. In contrast,

other genes were downregulated in these fibroblasts including NLRP2, FUCA1, CLCA4, and

RNF186 in Crohn's and RALGPS1, DLG3, STON2, and FMO5 in UC derived IBD Chips

(**Extended Data Fig. 3C,D**), which is again consistent with results of transcriptomic analyses

carried out on IBD patient tissues[31–33].

Gene ontology and Reactome analysis revealed that multiple IBD-relevant biological

processes, including increased ECM production and remodeling, cell adhesion, and

angiogenesis as well as decreased metabolism were predominant in both Crohn's and UC

epithelium and fibroblasts on-chip, with UC tissues also exhibiting suppressed IL10 signaling

(**Extended Data Fig. 4A-D**). These functional pathways are also activated or suppressed in a

similar manner in IBD patients[34].

Peristalsis-Like Mechanical Motions Enhance IBD Progression

IBD patients experience thinning of the protective mucus layer in their colon[12] and

eventually loss of peristalsis as a consequence of increased fibrosis[7,8], which further exacerbate

their gastrointestinal symptoms. However, it is not known whether cyclic mechanical

deformation of inflamed intestine or fluid flow due to peristalsis could influence IBD disease

progression. To explore this possibility, we cultured Healthy and IBD Chips in the presence or

absence of physiologically relevant cyclic deformations by applying suction to side chambers in

the flexible devices. The healthy and IBD epithelia both accumulated a mucus layer when

exposed to cyclic mechanical deformations were viewed by dark field imaging; however, the

layer was much thinner in the IBD Chips (**Fig. 2A,B**). Transcriptomic analysis confirmed that the

IBD Chips expressed lower levels of most mucins than Healthy Chips under all conditions, and

that while expression of MUC-1,4,12,13,17,3A,5AC, and 5B increased in Healthy Chips

exposed to mechanical strain, only MUC5AC and MUC13 increased in the IBD Chips (**Fig. 2C**).

These data show that peristalsis-like mechanical deformations have a direct effect on mucus

production in the colonic epithelium in both healthy and IBD Chips as fluid flow was constant

under all conditions, and that the IBD epithelium is less effective at maintaining the normal

thickness of the mucus layer in vitro as observed in IBD patients in vivo[12,13].

Interestingly, second harmonic imaging of ECM fiber formation on-chip revealed that

while both Crohn's and UC derived IBD fibroblasts accumulate comparable fibrillar collagen as

healthy cells, these levels increase many fold when the IBD Chips are exposed to peristalsis-

like motions whereas there is no change in Healthy Chips (**Fig. 2D,E**). Atomic force

microscopic analysis carried out in parallel samples from the biopsies we used to isolate the

patient-derived cells confirmed that this was associated with tissue stiffening (**Extended Data**

Fig. 5A-D). But while transcriptomic analysis showed that there is increased expression of

collagen-associated genes in Crohn's and UC stroma on-chip without mechanical strain,

exposure to peristalsis-like deformations did not result in significant changes in collagen gene

expression (**Fig. 2F**), suggesting that the fibrotic changes we observed resulted from post-

transcriptional alterations. Indeed, pathway analysis confirmed that biological processes

associated with fibrosis per se (ECM organization, collagen formation and fibril organization)

were upregulated in IBD Chips upon exposure to cyclic mechanical deformations (**Extended**

Fig. 6A). In addition, our transcriptomic analysis revealed that expression of different

cytochrome P450 subunits was suppressed in IBD versus Healthy Chips, which is consistent

with the observation that the intestinal tissues of IBD patients experience decreased metabolic

activities[35,36]. Importantly, while peristalsis-like cyclic deformations increased the expression of

most of these metabolic genes in Healthy Chips, this response was not observed in IBD Chips

(**Extended Data Fig. 6B**).

Peristalsis-like cyclic deformations also increased barrier function in both Healthy and

IBD Chips; however, barrier leakiness always remained higher in IBD Chips (**Extended Data**

Fig. 7A). Mechanical stimulation also enriched expression of inflammation associated genes in

epithelial cells and fibroblasts in both Healthy and IBD Chips (**Fig. 2G**) and this was supported

by transcriptomic analysis, which showed activation of the inflammatory response pathway in

these cells (**Extended Data Fig. 7B**). Importantly, further pathway analysis of this transcriptomic

dataset (**Extended Data Fig. 8**) demonstrated that peristalsis-like deformations activate

pathways associated with IBD progression and exacerbation in the epithelium, including those

involved in cancer, Toll-like receptor signaling, PPAR signaling, and focal adhesion in IBD

epithelium (**Extended Data Fig. 9A**) as well as NOD-like receptor signaling, PDGF signaling,

and cytokine-cytokine receptor interaction in IBD fibroblasts (**Extended Data Fig. 9B**). In

contrast, these pathways that are known to exacerbate colitis in IBD patients[37,38] were not

activated in Healthy Chips under the same mechanical stimulation conditions.

Replicating Sex-Specific Clinical Symptoms of IBD Patients

The gastrointestinal symptoms of female IBD patients become much more prominent

during menstrual periods[2] and their therapies need to be optimized to control their symptoms

before pregnancy due to increased risk to the fetus[3]. Yet, it is not known whether these

responses are a direct effect of ovarian hormones on the intestine[39]. To address this question

directly, we exposed healthy and IBD Chips lined by cells from female patients to estrogen (E2)

and medroxyprogesterone acetate (MPA) to recapitulate the menstrual cycle or a mixture of

pregnancy-associated hormones (E2, MPA, human chorionic gonadotropin, prolactin, and

placental lactogen) to mimic the first trimester of pregnancy. Interestingly, exposure to E2, MPA

or the pregnancy-associated hormone mixture decreased inflammatory cytokine and chemokine

production in Healthy Chips whereas levels of these inflammatory molecules increased when

IBD Chips were exposed to the same hormones (**Fig. 3A).** Moreover, addition of E2 and MPA

increased fibrosis and exposure to the pregnancy-associated hormone mixture produced an

even greater increase in fibrillar collagen deposition in the stroma of IBD Chips; however, this

was not observed in Healthy Chips (**Fig. 3B,C).**

Stromal Fibroblasts Control Barrier Permeability and Epithelial Inflammation

To better understand the role of fibroblasts in IBD, we took advantage of the synthetic

biology nature of human Organ Chip technology to create chips lined by heterotypic tissue

recombinants of healthy epithelium with IBD stroma and vice versa. As expected, the homotypic

cultures of IBD epithelium and stroma had a compromised barrier with higher permeability than

healthy epithelium and stroma recombinants (**Fig. 4A**). However, we discovered that the

presence of the IBD fibroblasts was the key driver of barrier disruption as permeability increased

significantly when they were combined healthy epithelium in tissue recombinant chips, even

though there was no difference in permeability when the different epithelia were cultured alone

(**Fig. 4A)**. Interestingly, the permeability of the IBD epithelium alone (i.e., without IBD stroma)

was similar to that of healthy epithelium with or without healthy fibroblasts, and tissue

recombinants combining healthy fibroblasts with IBD epithelium also did not further alter barrier

function, again emphasizing the key role of that the IBD stroma plays in terms of compromising

intestinal barrier function.

This controlling effect of IBD fibroblasts on barrier function when combined with healthy

epithelium was also accompanied by increased production of multiple inflammatory cytokines

and chemokines including IL-6, MCP-1 (**Fig. 4B**), IL-8, CXCL-1, LIF, IL-21, PIGF-1, and MIP-1b

(**Extended Data Fig. 10A**) relative to chips lined by healthy fibroblasts and epithelium or healthy

epithelium alone. However, the IBD epithelium appeared to constitutively express high levels of

all these cytokines regardless of whether or not IBD fibroblasts were present or they were

replaced with healthy fibroblasts, except for production of IL-6 and MCP-1 that were further

enhanced by the presence of the IBD stroma (**Fig. 4C** and **Extended Data Fig. 10B**). As these

two cytokines are known to promote monocyte infiltration into stroma from the vascular system

and their differentiation to macrophages cells[40], we perfused human peripheral blood

mononuclear cells (PBMCs) through the basal channel of the Colon Chips. We found that more

PBMCs adhered to the stroma and migrated to the epithelial channel in the IBD Chips

compared to Healthy Chips (**Fig. 4D**). While application of peristalsis-like deformations did not

alter PBMC adhesion to the stroma in the basal channel, it significantly enhanced the migration

of these cells to the epithelium in the apical channel, but only in IBD Chips (**Fig. 4E**). However,

when we carried out a similar study in a heterotypic tissue recombinant chip containing IBD

epithelium with healthy fibroblasts, PBMC recruitment and migration were suppressed and

reverted to the low levels observed in Healthy Chips (**Fig. 4D,E**). This finding correlates well

with transcriptomic analysis, which revealed that multiple surface receptors for immune cell

adhesion are expressed at higher levels in fibroblasts and epithelium in IBD Chips versus

Healthy Chips (**Extended Data Fig. 10C**). IBD Chips co-cultured with PBMCs also showed

increased production of IL-6 and IL-8 in both their apical and basal channels, whereas this was

not observed when Healthy Chips (**Extended Data Fig. 10D**).

Modeling Early Cancer Progression in Human IBD Chips

Patients with IBD have a higher incidence of colorectal cancer formation[41] and this also

has been demonstrated in animal IBD models by exposing them to the carcinogen ENU[42].

When we exposed Healthy and IBD Chips created with cells from multiple different donors to

ENU (1 mM) for 3 weeks, we observed a decrease in the height of crypt-like structures (**Fig.**

5A,B) and an increase in barrier permeability (**Fig. 5C**) in both in healthy and IBD Chips.

However, ENU had a much greater impact on inflammatory cytokine secretion in the IBD Chips

(**Fig. 5D**) and it resulted in a greater reduction of E-cadherin expression in IBD Chips versus

Healthy Chips, which was accompanied by a concomitant increase in β-catenin translocation to

the nucleus (**Fig. 5E,F**). Similar activation of the β-catenin signaling pathway has previously

been shown to be associated with colorectal cancer progression[43]. In addition, ENU treatment

promoted enlargement of epithelial nuclei and a decrease in their roundness, which are also

known to accompany early carcinogenesis[44]. Importantly, shallow pass genome sequencing

revealed increased gene mutations and duplication in IBD Chips, but not in Healthy Chips (**Fig.**

5G). Interestingly, the Crohn's chips exhibited a higher level of gene amplification than chips

lined with cells from UC patients, and an existing mutation in one Crohn's patient was further

amplified after ENU exposure.

Discussion

Taken together, these findings show that human Colon Chips created with primary

patient-derived colonic epithelium and fibroblasts from both healthy and IBD patients

recapitulate many features of their respective healthy and diseased phenotypes that are

observed in vivo. Based on its synthetic nature, this model enabled exploration of the roles of

stromal fibroblasts, epithelium, and immune cells, as well as fluid flow and peristalsis-like

mechanical deformations in the etiology of this disease. Importantly, our results revealed that

the stroma is a key driver of the IBD phenotype as it is appears to drive effects on intestinal

permeability, inflammation, and immune cell infiltration in human intestinal tissues. The finding

that IBD stromal fibroblasts respond differently to physiological peristalsis motions than healthy

fibroblasts and exhibits enhanced inflammation and fibrotic responses while fluid flow was

maintained constant also suggests that physiological mechanical deformations of intestine

during early stages of IBD development may feed back to further enhance inflammation and

fibrosis thereby accelerating disease progression. In addition, we found that ovarian hormones

influence the IBD phenotype directly by targeting the intestinal stroma. The greater

enhancement of inflammation and fibrosis we observed when IBD Chips were exposed to these

female hormones could be at least in part explain the exacerbation of IBD symptoms observed

in women versus men, particularly during pregnancy. Finally, we demonstrated that the human

IBD Chips also exhibit an enhanced sensitivity to a carcinogen and undergo changes that

underlie early stages of carcinogenesis in vitro, which is again consistent with the finding that

IBD patients have an increased propensity to develop colorectal cancers.

Our finding that intestinal stromal fibroblasts influence immune cell trafficking is

consistent with a past study in which knock out of genes expressed in an inflammatory subset of

fibroblasts produced a similar effect in a mice DSS colitis model[12]. These results raise the

possibility that human Colon Chips could be used as a preclinical model with IBD patient cells to

study the effects of emerging immune cell targeting therapies (e.g., anti-integrin $\alpha4\beta7$ to

suppress infiltration of circulating T-cells) on IBD stroma versus epithelium and to determine

their potential efficacy in a patient-specific manner[45]. In addition, this work might serve as

inspiration to develop other stroma-targeted therapies given our findings that the stroma is a key

driver of the IBD state in both females and males. The stroma also plays a critical role in

intestinal homeostasis by supporting the intestinal stem cell niche growth and modulating

immune responses, as well as protection against microbiota[46].

Another novel feature of this study is its relevance for Women's Health. Female IBD patients

can experienced loose and increased stools during the menstrual cycle as well as greater fetal

complications during pregnancy [39,47]. However, it has not been possible in the past to explore

whether or not these symptoms are the result of direct effects of female hormones on intestinal

tissues. This is because female hormone research is challenging using animals. For example,

mice that are often used for women's health research[48] do not menstruate like humans do (e.g.,

they undergo an estrous cycle) and their immune responses different significantly from human[49].

Consistent with clinical observations, we found that female hormones exacerbate inflammation

and fibrosis in IBD Chips, but not in Healthy Chips, with pregnancy-like conditions producing

even greater effects. Thus, these data demonstrate for the first time that at least part of the

excerbations observed in female patients is likely due to direct effects on the intestinal tissues,

and particular on the stroma where fibrosis is greatly enhanced.

In addition to increased inflammation and decreased mucus production, lack of intestinal

motion due to fibrosis is a hallmark of IBD; however, it has not been previously possible to

explore whether peristalsis plays a role in earlier stages of IBD progression. We found that

peristalsis-like mechanical deformations increased production of the protective mucus layer in

Healthy Chips, but less so in IBD Chips, and that these mechanical cues also enhanced

inflammation and fibrosis, but only in IBD Chips. This suggests that persistence of physiological

peristalsis during early stages of inflammation may promote progression of IBD, and that fibrosis

and resultant suppression of peristalsis likely occur at a later stage in this process. This may, in

part, occur because the IBD tissues lose their ability to maintain the mucus barrier that protects

against dysbiotic microbiome and pathogens that are known to be enriched in the microbiome of

IBD patients, such as *Ruminococcus* family members that degrade mucus[50]. This could then

lead to more inflammation and a positive feedback loop characterized by enhanced sensitivity to

these mechanical deformations resulting in greater increases in inflammation, ECM

accumulation, and fibrosis at later stages of the disease, which stiffens the mucosa and

physically restricts tissue distension.[41]

Chronic inflammation in patients with IBD is known to be a risk factor for increased cancer

formation. Importantly, our results show that human IBD tissues do indeed exhibit an enhanced

sensitivity to a carcinogen (ENU) compared to Healthy colon tissues on-chip, as indicated by

crypt blunting, loss of adherent junctions, and localization of β-catenin to the nucleus as seen in

IBD patient tissues that progressed to colorectal cancer[51]. Importantly, we also observed a

greatly increased inflammatory response as well as accelerated development of cancer-

associated mutations and chromosomal amplifications in IBD Chips but not Healthy Chips, even

though immune cells were not present. While similar effects have been observed after exposure

to ENU in a murine intestine model [52], this to our knowledge is the first demonstration of early

cancer progression in a preclinical *human* IBD model. Although it has been believed that both

Crohn's and UC patients carry a similarly high risk of cancer progression [53], many Crohn's

patients undergo colectomy early in the course of the disease to alleviate persistent

symptoms[54], and this effectively eliminates their risk of developing colorectal cancer.[59]

Interestingly, although our sampling was small, we found that ENU induced greater gene and

chromosomal aberrations in Crohn's patient tissues than in UC patient chips, suggesting that

they might exhibit a greater susceptibility to carcinogens. This is a finding which should be

followed up in clinical studies in the future.

The incidence of IBD is anticipated to increase in the upcoming years. Limitations in the

ability of in vivo models to represent human IBD physiology are evident, as the most commonly

used anti-TNF and anti-IL-12/23p40 antibodies, which benefit patients with IBD, are generally

not effective in chemically-induced colitis models[55]. The need for modeling IBD using Organ

Chip technology also has been acknowledged by leading IBD organizations, such as the

Crohn's and Colitis Foundation[56]. Therefore, we believe this novel microfluidic disease model

brings important opportunities for IBD treatment, management, and drug development. As we

can analyze outflows from the epithelial and stromal compartments separately and through use

of tissue recombinants, this method also may facilitate discovery of potential stool and blood

biomarkers of IBD progression and cancer risk. Use of tissue recombinants is a powerful

method for analyzing epithelial-mesenchymal interactions in commonly used developmental

biology research, which as we show here also may be applied to confront similar questions

relating to human epithelial-stromal interactions, which are challenging to address in vivo. In

addition to enabling study of the effects of female hormones on IBD, and it also could allow

investigation of other IBD subcategories, including very early onset (VEO-IBD), adolescent IBD,

and genetic forms of the disease by lining chips with relevant patient cells. Finally, given the

synthetic nature of the model and as living gut microbiome can be co-cultured in these Intestine

Chips for extended times[15,57], this experimental system also may be used to study how other

environmental factors (e.g., pathogens, diet, etc.) contribute to development of the IBD

phenotype in the future.

Methods

Acquisition of human colon tissue and cells

Healthy colon tissue samples were collected from macroscopically grossly unaffected

regions of the colon of de-identified healthy adult patients undergoing endoscopy for non-IBD

related complaints, such as diverticulitis. IBD tissue samples were collected from endoscopic

tissue biopsies from newly diagnosed IBD patients with either Crohn's disease or Ulcerative

Colitis. Informed consent and developmentally appropriate assent were obtained at Boston

Children's Hospital and McGill University Health Centre from the donors' guardians and the

donor, respectively. All methods were performed in accordance with the Institutional Review

Board of Massachusetts General Hospital approval (protocol number IRB-2015P001859) and

McGill University Health Centre (protocol number REB-2007-856). We generated epithelium-

derived organoids (colonoids) that were cultured in Matrigel using published methods[13,15]and

isolated stromal fibroblasts from the same IBD tissues from 3 Crohn's and 3 UC patients, which

were cultured in fibroblast medium (FM, CC-3132, Lonza, MA) in 75 cm^2 flasks (3531135,

Falcon, Durham, NC). Healthy colonoids and fibroblasts were isolated from areas with normal

histology adjacent to regions of diverticulitis from 3 otherwise healthy patients (**Supplementary**

Table 1). All reagents and resources were provided in **Supplementary Table 2**.

Human Colon Chip Cultures

Our methods for creating and culturing human Colon Chips lined by primary intestinal

organoid-derived epithelium using commercially available Organ Chip Devices (Basic Research

Kit; Emulate Inc.) have been described previously[13,16] and are described in greater detail in

Supplementary Materials. Colonoids cultured were released from Matrigel and fragmented by

treatment with TrypLE Express Enzyme (12605010; Thermo Fisher Scientific), before being

seeded in the apical channel of the 2-channel Organ Chip devices and incubated overnight at

37°C under 5% CO_2 to promote adhesion. One day later, channels were washed with

Expansion Medium (EM; Harvard Digestive Diseases Center Organoid Core, MA) to remove

unattached cells, and then perfused with EM (60 µL/hr). At this time, the cultured fibroblasts

were detached enzymatically and seeded in EM in the basal channel for 2 h under static

conditions to promote adhesion. After washing, EM was then perfused through both channels at

60 µL/h. After 3 days of co-culture during which both epithelial and fibroblast monolayers were

established, EM perfused through the apical channel was changed to Hank's balanced salt

solution (HBSS) with calcium and magnesium (21-023-cv; Corning) supplemented with 100

mg/mL Primocin (ant-pm-1; InvivoGen) while EM remained flowing through the basal channel.

For experiments exploring the role of physiological peristalsis-like motions, cyclic mechanical

strain (10% Strain 0.15 Hz) was applied to the tissues by applying cyclic suction to side

chambers of the flexible device[15,16] for 2 weeks after seeding. Methods for morphological

analysis, cytokine quantification, flow cytometry, transcriptional analysis, and atomic force

microscopy can be found in **Supplementary Information**.

Maternal Hormone Treatment

Established Healthy and IBD Colon Chips were exposed to different combinations of

hormones from basal channel to recapitulate either the menstrual cycle or first trimester of

pregnancy. Chips were treated with 17β-estradiol (E2, 10 nM, Sigma, E4389) for 3 days before

being exposed to medroxyprogesterone 17-acetate (MPA, 1 μM, Sigma, 46412-250MG) for an

additional 4 days to mimic the menstrual period of the cycle. Chips perfused for 3 days with E2

were then treated with E2, MPA, Prolactin (PRL, 20 ng/mL, VWR, 103681-334), Human

Placental Lactogen (hPL/ CSH1, 20 ng/ml, VWR, 103681-334), and Human Chorionic

Gonadotropin (HCG, 1 μg/mL, VWR, IC0219859110) for 4 days to recapitulate the first trimester

of pregnancy as described previously[17,18].

Immune Cell Recruitment Assay

Colon Chips were cultured for 2 weeks before human peripheral blood mononuclear

cells (PBMCs) were added to the cultures for studies on immune cell adhesion and migration.

PBMCs were collected from anonymous donors undergoing stem cell mobilization at the

Massachusetts General Hospital (MGH) under Institutional Review Board approved protocol

#2015P001859. PBMCs were freshly isolated by density centrifugation using the Lymphoprep

protocol (StemCell Technologies, #07801), resuspended in 10 ml of DMEM containing 10%

FBS and 1% Penicillin-Streptomycin, and labeled with 10 μl of CellTracker Deep Red at a final

concentration of 10 μM (Invitrogen, #C7025) for 20 minutes at 37°C. The labeled cells were

centrifuged and resuspended to a concentration of 5×10^7 cells/ml and 25 μl of the PBMC

suspension was added to the lower channel (see **Supplementary Information** for more

details).

Analysis of effects of carcinogen exposure

To explore if the chip models can be used to study the effects of intestinal tissue to

carcinogen exposure in vitro, Healthy and IBD Colon Chips were exposed to 1 μg/mL of N-ethyl-

N-nitrosourea (ENU), which was flowed through both the apical and basal channels at 60 μL/hr.

Chips were harvested for DNA isolation three weeks after ENU exposure. Briefly, chips were

washed with DPBS (-/-) and incubated with TrypLE consisting of 2 mg/mL collagenase and 10

μM Y-27632 at 37°C for 1 h. Single cells were washed with DPBS (-/-) and DNA was isolated by

following the manufacturer's protocol (Qiagen Micro DNA isolation kit, Cat: 56304 Qiagen,

Germany). Shallow whole genome sequencing was performed in two batches using different

methods (see **Supplementary Information**). The raw sequence reads were mapped to *Homo*

sapiens GRCh38 with Burrows-Wheeler Alignment Tool v0.7.17[19]. Reads with a mapping quality

of less than 37 were removed from further analysis. The PCR duplicates and base quality

recalibration were subsequently carried out using Genome Analysis Toolkit (GATK) v4.4.0[20] and

Picard v2.27.5. The copy number of the genome was then estimated and profiled with ACE

v3.16[21] and QDNAseq v1.35.0 R package[22] using 100 Mb fixed-sized bins.

Statistical Analysis

Data in all graphs are expressed as mean ± standard deviation (SD) and significant

differences between multiple groups were determined using an unpaired Students t-test, one-

way analysis of variance (ANOVA) or two-way ANOVA with Tukey test for correction unless

otherwise indicated in the figure legends. $P < 0.05$ was considered significant. Data were

analyzed using GraphPad Prism 8 software (GraphPad Software, San Diego, CA).

Acknowledgement

This work was funded in part by Cancer Research UK (C19767/A27145 to DEI) and by

the Wyss Institute for Biologically Inspired Engineering at Harvard University as well as by an

NIH training grants (5T32DK007199-44 and 5T32EB016652-10 to AO). We thank Harvard

Digestive Diseases Center Organoid Core for providing L-WRN conditioned media.

Contributions

A.O., S.H. and D.E.I designed the research; A.O., G.E.M, R.R.P. A.S. K. C., E. C. performed the

experiments; A.O., G.E.M., R.R.P. A.S., K.C., E.C. analyzed and interpreted the data; A.O. and

G.E.M. established IBD human organoid and fibroblast biobanks; V. H., M. S. and A.O.

performed bioinformatic analysis; D.B.C., L.E.F., R.R., L.B. provided the clinical samples; A.O.

and D.E.I. acquired the funding; A.O. wrote the articled with input from G.G., S.H. and D.E.I.;

and all authors reviewed, discussed and edited the manuscript.

Data and code availability

Competing interests

D.E.I. holds equity in Emulate, chairs its scientific advisory board and is a member of its board

of directors. The other authors declare no competing interests.

References

1. Friedrich, M. *et al.* IL-1-driven stromal–neutrophil interactions define a subset of patients
with inflammatory bowel disease that does not respond to therapies. *Nat Med* **27**, 1970–
1981 (2021).

2. Goodman, W. A., Erkkila, I. P. & Pizarro, T. T. Sex matters: impact on pathogenesis,
presentation and treatment of inflammatory bowel disease. *Nature Reviews*
Gastroenterology & Hepatology 2020 17:12 **17**, 740–754 (2020).

3. Watermeyer, G. Pregnancy and inflammatory bowel disease. *South African*
Gastroenterology Review **5**, 4–6 (2007).

4. Sarvestani, S. K. *et al.* Cancer-predicting transcriptomic and epigenetic signatures
revealed for ulcerative colitis in patient-derived epithelial organoids. *Oncotarget* **9**,
28717–28730 (2018).

5. Ingber, D. E. Cancer as a disease of epithelial–mesenchymal interactions and
extracellular matrix regulation. *Differentiation* **70**, 547–560 (2002).

6. Smillie, C. S. *et al.* Intra- and Inter-cellular Rewiring of the Human Colon during Ulcerative
Colitis. *Cell* **178**, 714-730.e22 (2019).

7. Rieder, F. & Fiocchi, C. Intestinal fibrosis in IBD - A dynamic, multifactorial process. *Nat*
Rev Gastroenterol Hepatol **6**, 228–235 (2009).

8.   Guglielmo, F. F. *et al.* Identifying decreased peristalsis of abnormal small bowel
segments in Crohn's disease using cine MR enterography: the frozen bowel sign. *Abdom*
Imaging **40**, 1150–1156 (2015).

9.   Joshi, A., Soni, A. & Acharya, S. In vitro models and ex vivo systems used in
inflammatory bowel disease. *In vitro models 2022 1:3* **1**, 213–227 (2022).

10.   Özkan, A., LoGrande, N. T., Feitor, J. F., Goyal, G. & Ingber, D. E. Intestinal organ chips
for disease modelling and personalized medicine. *Nat Rev Gastroenterol Hepatol* 1–23
(2024) doi:10.1038/s41575-024-00968-3.

11.   Ingber, D. E. Human organs-on-chips for disease modelling, drug development and
personalized medicine. *Nat Rev Genet* **23**, 467–491 (2022).

12.   Gustafsson, J. K. & Johansson, M. E. V. The role of goblet cells and mucus in intestinal
homeostasis. *Nat Rev Gastroenterol Hepatol* **19**, 785–803 (2022).

13.   Sontheimer-Phelps, A. *et al.* Human Colon-on-a-Chip Enables Continuous In Vitro
Analysis of Colon Mucus Layer Accumulation and Physiology. *Cmgh* **9**, 507–526 (2020).

14.   Tovaglieri, A. *et al.* Species-specific enhancement of enterohemorrhagic E. coli
pathogenesis mediated by microbiome metabolites. *Microbiome* **7**, 1–21 (2019).

15.   Jalili-Firoozinezhad, S. *et al.* A complex human gut microbiome cultured in an anaerobic
intestine-on-a-chip. *Nat Biomed Eng* **3**, 520–531 (2019).

16.   Tovaglieri, A. *et al.* Species-specific enhancement of enterohemorrhagic E. coli
pathogenesis mediated by microbiome metabolites. *Microbiome* **7**, 1–21 (2019).

17.   Turco, M. Y. *et al.* Long-term, hormone-responsive organoid cultures of human
endometrium in a chemically defined medium. *Nat Cell Biol* **19**, 568–577 (2017).

18.   Gnecco, J. S. *et al.* Organoid co-culture model of the human endometrium in a fully
synthetic extracellular matrix enables the study of epithelial-stromal crosstalk. *Med* **4**,
554-579.e9 (2023).

19.   Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows–Wheeler
transform. *Bioinformatics* **25**, 1754–1760 (2009).

20.   Genomics in the Cloud: Using Docker, GATK, and WDL in Terra - Geraldine A. Van der
Auwera, Brian D. O'Connor - Google Books.
https://books.google.com/books?hl=en&lr=&id=vsXaDwAAQBAJ&oi=fnd&pg=PP1&dq=V
an+der+Auwera+GA+%26+O%27Connor+BD.+(2020).+Genomics+in+the+Cloud:+Using
+Docker,+GATK,+and+WDL+in+Terra+(1st+Edition).+O%27Reilly+Media.&ots=5lcr0E-
qna&sig=43MTbQQNO_yexxB7NxDgVt88kOk#v=onepage&q&f=false.

21. Poell, J. B. *et al.* ACE: absolute copy number estimation from low-coverage whole-
genome sequencing data. *Bioinformatics* **35**, 2847–2849 (2019).
22. Scheinin, I. *et al.* DNA copy number analysis of fresh and formalin-fixed specimens by
shallow whole-genome sequencing with identification and exclusion of problematic
regions in the genome assembly. *Genome Res* **24**, 2022–2032 (2014).
23. Chan, C. W. M. *et al.* Gastrointestinal differentiation marker Cytokeratin 20 is regulated
by homeobox gene CDX. *Proc Natl Acad Sci U S A* **106**, 1936–1941 (2009).
24. West, N. R. *et al.* Oncostatin M drives intestinal inflammation and predicts response to
tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease.
Nat Med **23**, 579–589 (2017).
25. Wu, J. *et al.* Therapeutic targeting of vimentin by ALD-R491 impacts multiple pathogenic
processes to attenuate acute and chronic colitis in mice. *Biomedicine & Pharmacotherapy*
168, 115648 (2023).
26. Torres, J. *et al.* Serum Biomarkers Identify Patients Who Will Develop Inflammatory
Bowel Diseases Up to 5 Years Before Diagnosis. *Gastroenterology* **159**, 96–104 (2020).
27. Danese, S., Sans, M. & Fiocchi, C. The CD40/CD40L costimulatory pathway in
inflammatory bowel disease. *Gut* **53**, 1035 (2004).
28. Liu, Z. *et al.* Genetic architecture of the inflammatory bowel diseases across East Asian
and European ancestries. *Nat Genet* **55**, 796 (2023).
29. Tian, T., Wang, Z. & Zhang, J. Pathomechanisms of Oxidative Stress in Inflammatory
Bowel Disease and Potential Antioxidant Therapies. *Oxid Med Cell Longev* **2017**,
4535194 (2017).
30. Stokkers, P. C. F., Reitsma, P. H., Tytgat, G. N. J. & Van Deventer, S. J. H. HLA-DR and
-DQ phenotypes in inflammatory bowel disease: a meta-analysis. *Gut* **45**, 395 (1999).
31. Yu, W. *et al.* Association of a Nkx2-3 polymorphism with Crohn's disease and expression
of Nkx2-3 is up-regulated in B cell lines and intestinal tissues with Crohn's disease. *J*
Crohns Colitis **3**, 189–195 (2009).
32. WO2019018571A1 - Methods and uses of inflammatory bowel disease biomarkers -
Google Patents. https://patents.google.com/patent/WO2019018571A1/en.
33. Srivastava, M., Zurakowski, D., Cheifetz, P., Leichtner, A. & Bousvaros, A. Elevated
Serum Hepatocyte Growth Factor in Children and Young Adults With Inflammatory Bowel
Disease. *J Pediatr Gastroenterol Nutr* **33**, 548–553 (2001).

34. Cheng, C. *et al.* Identification of differentially expressed genes, associated functional
terms pathways, and candidate diagnostic biomarkers in inflammatory bowel diseases by
bioinformatics analysis. *Exp Ther Med* **18**, 278–288 (2019).

35. Wilson, A. *et al.* Crohn's Disease Is Associated with Decreased CYP3A4 and P-
Glycoprotein Protein Expression. *Mol Pharm* **16**, 4059–4064 (2019).

36. Sen, A. & Stark, H. Role of cytochrome P450 polymorphisms and functions in
development of ulcerative colitis. *World J Gastroenterol* **25**, 2846 (2019).

37. Dubuquoy, L. *et al.* PPARγ as a new therapeutic target in inflammatory bowel diseases.
Gut **55**, 1341 (2006).

38. Ashton, J. J. *et al.* Deleterious Genetic Variation Across the NOD Signaling Pathway Is
Associated With Reduced NFKB Signaling Transcription and Upregulation of Alternative
Inflammatory Transcripts in Pediatric Inflammatory Bowel Disease. *Inflamm Bowel Dis*
28, 912–922 (2022).

39. Lim, S. M. *et al.* The effect of the menstrual cycle on inflammatory bowel disease: A
prospective study. *Gut Liver* **7**, 51–57 (2013).

40. Chomarat, P., Banchereau, J., Davoust, J. & Karolina Palucka, A. IL-6 switches the
differentiation of monocytes from dendritic cells to macrophages. *Nature Immunology*
2000 1:6 **1**, 510–514 (2000).

41. Murphy, C. C. & Zaki, T. A. Changing epidemiology of colorectal cancer — birth cohort
effects and emerging risk factors. *Nat Rev Gastroenterol Hepatol* **21**, 25–34 (2023).

42. Schmitt, M. & Greten, F. R. The inflammatory pathogenesis of colorectal cancer. *Nat Rev*
Immunol **21**, 653–667 (2021).

43. Herzig, M., Savarese, F., Novatchkova, M., Semb, H. & Christofori, G. Tumor progression
induced by the loss of E-cadherin independent of β-catenin/Tcf-mediated Wnt signaling.
Oncogene **26**, 2290–2298 (2007).

44. Zink, D., Fischer, A. H. & Nickerson, J. A. Nuclear structure in cancer cells. *Nature*
Reviews Cancer 2004 4:9 **4**, 677–687 (2004).

45. D'Alessio, S. *et al.* Revisiting fibrosis in inflammatory bowel disease: the gut thickens. *Nat*
Rev Gastroenterol Hepatol **19**, 169–184 (2022).

46. Ryan, F. J. *et al.* Colonic microbiota is associated with inflammation and host epigenomic
alterations in inflammatory bowel disease. *Nat Commun* **11**, 1–12 (2020).

47. Mendelson, S., Anbukkarasu, P., Cassisi, J. E. & Zaman, W. Gastrointestinal functioning
and menstrual cycle phase in emerging young adult women: a cross-sectional study.
BMC Gastroenterol **23**, 1–10 (2023).

48.   Bellofiore, N., Ellery, S., Mamrot, J., … D. W.-A. journal of & 2017, undefined. First

572   evidence of a menstruating rodent: the spiny mouse (Acomys cahirinus). *Elsevier*.

573   49.   Bellofiore, N., Cousins, F., Temple-Smith, P., Dickinson, H. & Evans, J. A missing piece:

574   the spiny mouse and the puzzle of menstruating species. *J Mol Endocrinol* **61**, R25–R41

575   (2018).

576   50.   Paone, P. & Cani, P. D. Mucus barrier, mucins and gut microbiota: the expected slimy

577   partners? *Gut* **69**, 2232 (2020).

578   51.   Aust, D. E. *et al.* Altered distribution of β-catenin, and its binding proteins E-cadherin and

579   APC, in ulcerative colitis-related colorectal cancers. *Modern Pathology* **14**, 29–39 (2001).

580   52.   Winton, D. J. & Ponder, B. A. J. Stem-cell organization in mouse small intestine. *Proc Biol*

581   *Sci* **241**, 13–18 (1990).

582   53.   Winawer, S. J. *et al.* Colorectal Cancer Screening: Clinical Guidelines and Rationale The

583   Adenoma-Carcinoma Sequence. *Gastroenterology* **112**, 594–642 (1997).

584   54.   Gillen, C. D., Walmsley, R. S., Prior, P., Andrews, H. A. & Allan, R. N. Ulcerative colitis

585   and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis. *Gut*

586   **35**, 1590 (1994).

587   55.   Pizarro, T. T. *et al.* Challenges in IBD Research: Preclinical Human IBD Mechanisms.

588   *Inflamm Bowel Dis* **25**, S5–S12 (2019).

589   56.   Heller, C. A. *et al.* Challenges in IBD Research. *Inflamm Bowel Dis* **25**, S31–S39 (2019).

590   57.   Kim, H. J., Huh, D., Hamilton, G. & Ingber, D. E. Human gut-on-a-chip inhabited by

591   microbial flora that experiences intestinal peristalsis-like motions and flow. *Lab Chip* **12**,

592   2165–2174 (2012).

Figure Legends

Figure 1: Primary human Colon Chips generated with epithelium and fibroblasts isolated from Healthy and IBD patient samples. A) Photograph of the commercially available Organ Chip device (left) and a cross-sectional illustration of the epithelial-stromal tissue interface (right) formed with patient-derived cells, which is composed of a fibroblast rich stroma that is perfused with medium to mimic interstitial fluid flow separated by a flexible, porous, ECM-coated membrane from a colon epithelium above. The epithelium, which is composed of absorptive cells and Goblet cells, secretes a thick mucus layer into the lumen of the apical channel that also experiences fluid flow. The entire tissue-tissue interface can be stretched and relaxed rhythmically to mimic peristalsis-like motions by applying cyclic suction to hollow side chambers in the flexible device (not shown). **B)** Height of crypts formed in Colon Chips measured at 11 days. Numbers indicate P values between compared groups, as determined by one-way ANOVA test (n=3 Healthy, green; 2 Crohn's, magenta; and 2 UC, cyan). **C)** Representative bright field microscopic images of Healthy and IBD Chips created with cells from Crohn's or UC patients viewed from above on day 3, 7, and 11. A functional epithelial monolayer progressively accumulated mucus, which appears as opaque blackened fuzzy material, in the apical channel of all chips over the 11 day time course; however, mucus accumulation was suppressed in the IBD Chips with the UC Chips displaying a greater reduction (bar, 500 μm). **D)** Brightfield image of vertical cross-sections through healthy and IBD Colon chips showing that the crypt-like epithelial structures are shorter in the Crohn's and UC Colon Chips (bar, 100 μm). **E)** Histological H&E stained vertical cross-sections through healthy and IBD Colon chips confirming the presence of columnar colon epithelium containing goblet cells in healthy epithelium, and a significant reduction in the height of the epithelial monolayer with reduced numbers of goblet cells in the IBD Chips (bar, 50 μm). **F)** Immunofluorescence microscopic views showing distribution of SOX9 and CK20 in crypts in the colon epithelium of

Healthy and IBD Chips (bar, 50 μm). **G**) Inflammatory cytokine protein levels measured in the

basal outflows of Healthy (H) and IBD Chips on culture day 11 (n = 3-5 chips/ condition; chips

were created with cells from 3 healthy (green), 2 Crohn's (magenta), and 2 UC (cyan) patient

donors, with each symbol represents a chip created with cells from a different patient. Numbers

indicate *P* values between compared groups, as determined by two-tailed student's t-test. All

data represent mean $\pm$ SD; *p* values are shown in all figures.

Figure 2: Peristalsis-like cyclic strain influences mucus production and fibrosis in

Colon Chips. A) Representative side-view images microscopy of Healthy or IBD Chips with (+)

and without (-) exposure to mechanical deformations visualizing mucus layer accumulation

(white diffuse material) in Healthy Chips using dark-field microscopy. Note that limited mucus

was produced by IBD epithelium (bar, 1 mm). **B)** Quantification of the height of the mucus layer

overlying Healthy and IBD epithelium on-chip when cultured under the conditions in A. Numbers

indicate *P* values between compared groups, as determined by one-way ANOVA test. (n = 4

healthy, green; 2 Crohn's, magenta; and 2 UC, cyan). **C)** Heat map of genes showing that

peristalsis-like mechanical stimulation (+) increases expression of genes related to mucus

production in Healthy Chips, but not IBD Chips (n = 3 healthy, 1 Crohn's and 2 UC). **D)** Second

harmonic microscopic images of the fibroblast stroma in Healthy versus IBD Chips showing

greater collagen fibril accumulation (green) with mechanical strain (+ Strain) in both chips, and

that this response is greatly accentuated in IBD Chips (bar, 200 μm). **E)** Collagen fibril signal

intensity in the stroma of Healthy versus IBD Chips quantified in second harmonic microscopic

images. Numbers indicate *P* values between compared groups, as determined by one-way

ANOVA test (n = 3 healthy, green; 2 Crohn's, magenta; and 2 UC, cyan). **F)** Heat map of genes

showing that peristalsis-like cyclic strain enhances expression of genes associated with fibrillar

collagen production in IBD fibroblasts, but not in healthy fibroblasts (n = 3 healthy, 1 Crohn's

and 2 UC). **G)** Heat maps of showing that cyclic strain enhances greater expression of IBD-

associated inflammatory genes in IBD Chips compared to Healthy Chips both in epithelium and

fibroblasts (n=3 Healthy, 1 Crohn's, and 2 UC).

Figure 3: Effects of ovarian hormones in Female Colon Chips. A) Production of pro-

inflammatory cytokine and chemokine proteins in Apical and Basal channels of Healthy versus

IBD Chips 7 days post treatment with different female hormone exposures (E2, P4, and PAHs,

as indicated). Note that exposure to female hormones significantly increased expression of

inflammatory factors in both epithelium and fibroblast of IBD Colon Chips whereas they

suppressed their production in Healthy Chips. **B)** Collagen fibril signal intensity in the stroma of

Healthy versus IBD Chips quantified in second harmonic microscopic images showing that only

exposure to pregnancy-like hormonal conditions produced a major increase in stromal

fibrillogenesis, and this only was observed in IBD fibroblasts and not healthy fibroblasts from

IBD patients. Numbers indicate P values between compared groups, as determined by one-way

ANOVA test (n=4-6 chips of 1 Crohn's and 1 Healthy patients from 2 independent experiments).

C) Second harmonic microscopic images of fibrillar collagen (green) produced by fibroblasts

showing that the E2 + E4 produce a small increase in fibrillogenesis in IBD Chips, while

simulating pregnancy by exposure to E2 + E4 + PAH results in dramatic collagen fibril

accumulation, and that neither of these responess are observed in Healthy Chips (bar, 200 μm;

n=4-6 chips of 1 Crohn's and 1 Healthy patients from 2 independent experiments).

Figure 4: Tissue recombinant chips reveal that the IBD fibroblasts drive

compromise of the permeability barrier and inflammation in the epithelium. **A)** Graphs

showing that intestinal barrier permeability to cascade blue is much higher in homotypic IBD

Chips compared to Healthy Chips and that tissue recombinants of IBD fibroblasts with healthy

(H) epithelium results in a similar high level of barrier compromise on-chip. This is not observed

in the IBD or healthy epithelium in the absence of fibroblasts or in IBD epithelium with healthy

fibroblasts. Numbers indicate P values between compared groups, as determined by one-way

ANOVA test (n = 3 healthy, green; 2 Crohn's, magenta; and 2 UC, cyan). **B)** Quantification of

cytokine protein levels revealed that combination of IBD fibroblasts with healthy epithelium

results in increased production of IL-6 and MCP-1 in Colon Chips, whereas this was not seen in

healthy epithelium alone or homotypic Colon Chips. Numbers indicate *P* values between

compared groups, as determined by one-way ANOVA test (n = 3 healthy, green; 1 Crohn's,

magenta; and 2 UC, cyan). **C)** IL-6 and MCP-1 production by IBD epithelium also required the

presence of IBD fibroblasts. Numbers indicate *P* values between compared groups, as

determined by one-way ANOVA test (n = 3 healthy, green; 1 Crohn's, magenta; and 2 UC,

cyan). **D)** Peristalsis-like cyclic strain preferentially stimulates migration of PBMCs (magenta)

from the fibroblast stroma in the basal channel (Basal) to the epithelium in the apical channel

(Apical) in IBD Chips but not in heterotypic chips with IBD epithelium and healthy fibroblasts or

in Healthy Chips. **E)** Quantification of the results from **D** confirmed that IBD Chips exhibited

higher baseline recruitment of PBMCs to the surface of the fibroblast stroma in the basal

channel and that this was not altered by mechanical strain, whereas IBD epithelium combined

with healthy stroma or Healthy Chips only displayed significantly less PBMC recruitment. In

contrast, the number of PBMCs that migrated to the epithelium in the Apical channel more than

doubled in IBD Chips when they were exposed to peristalsis-like mechanical deformations, and

overall migration of PBMCs was minimal when IBD fibroblasts were absent. Numbers indicate

P values between compared groups, as determined by one-way ANOVA test (n = 2 healthy,

green; 1 Crohn's, magenta; and 1 UC, cyan).

Figure 5: Exposure to carcinogen preferentially promotes mutagenesis and early

steps in carcinogenesis in IBD Chips. A) DIC images of the epithelium when viewed from

above in Healthy (H) and IBD Chips after 21 days of culture in the presence or absence of the

carcinogen (ENU) showing that undulating crypt-like structures are lost in both Healthy and IBD

Chips after exposure to ENU (bar, 500 μm). **B)** Quantification of results from **A** showing that

ENU decreases height of the epithelium in both healthy and IBD Colon Chips. Numbers indicate

P values between compared groups, as determined by one-way ANOVA test (n = 4 healthy,

green; 2 Crohn's, magenta; and 2 UC, cyan). **C)** Epithelial barrier permeability increased as a

result of exposure to ENU in Healthy and IBD Chips. Numbers indicate *P* values between

compared groups, as determined by one-way ANOVA test. (n = 3 healthy, green; 2 Crohn's,

magenta; and 2 UC, cyan). **D)** Heatmaps showing inflammatory cytokine protein levels

measured in outflows from the apical channel of Healthy and IBD Chips 3 weeks post-ENU

exposure. Importantly, ENU exposure significantly increased inflammatory cytokine production

in IBD Chips made with cells from both Crohn's and UC patients compared to healthy patients.

E) Confocal microscopic top-view images showing β-catenin and E-cadherin localization and

nuclear staining (DAPI) in the epithelium within Healthy and IBD Chips 3 weeks post-ENU

exposure (bar, 20 μm). **F)** Quantification of protein staining intensity and morphology reveal that

ENU exposure decreases E-cadherin levels and increases nuclear localization of β-catenin in

IBD patient-derived Colon Chips compared to Healthy Chips. ENU exposure also resulted in

greater nucleus size and less roundness. Numbers indicate *P* values between compared

groups, as determined by Student's t-test (n = 3 healthy, green; 2 Crohn's, magenta; and 2 UC,

cyan). **G)** Plots showing copy number changes across all human chromosomes in Healthy and

IBD Chips pre- (red) and 3 weeks post-ENU exposure (blue). Green bars indicate amplification

of gene sequences for the whole chromosome. Each symbol represents an individual Healthy or

IBD patient-derived chip.

Fig. 1

Fig. 2

Fig. 3

Fig. 4

Control/**ENU(3 weeks)**

Fig. 5

Extended Data Fig. 1

Extended Data Fig. 2

Extended Data Fig. 3

A

B

C

D

Extended Data Fig. 4

Extended Data Fig. 6

A

B

GOBP INFLAMMATORY RESPONSE
+Strain vs - Strain Healthy Colon Chip (Epithelium)

Adj p-val: <0.00010
NES: 1.78

GOBP INFLAMMATORY RESPONSE
+Strain vs -Strain IBD Colon Chip (Epithelium)

Adj p-val: <0.00010
NES: 2.13

Extended Data Fig. 7

Extended Data Fig. 8

A

KEGG PATHWAYS IN CANCER
+Strain vs -Strain IBD Colon Chips (Epithelium)

Adj p-val: <0.00010
NES: 1.72

KEGG TOLL LIKE RECEPTOR SIGNALING PATHWAY
+Strain vs -Strain IBD Colon Chips (Epithelium)

Adj p-val: 0.00084
NES: 1.86

KEGG PPAR SIGNALING PATHWAY
+Strain vs -Strain IBD Colon Chips (Epithelium)

Adj p-val: 0.03928
NES: 1.64

GOBP VASCULATURE DEVELOPMENT
+Strain vs -Strain IBD Colon Chips (Epithelium)

Adj p-val: <0.00010
NES: 2.32

KEGG FOCAL ADHESION
+Strain vs -Strain IBD Colon Chips (Epithelium)

Adj p-val: <0.00010
NES: 2.06

KEGG CYTOKINE CYTOKINE RECEPTOR INTERACTION
+Strain vs -Strain IBD Colon Chips (Epithelium)

Adj p-val: <0.00010
NES: 2.24

KEGG ECM RECEPTOR INTERACTION
+Strain vs -Strain IBD Colon Chips (Epithelium)

Adj p-val: <0.00010
NES: 2.25

Genes more highly expressed in epithelial IBD strain homotypic

Genes more highly expressed in epithelial IBD no strain homotypic

B

KEGG CYTOKINE CYTOKINE RECEPTOR INTERACTION
+Strain vs -Strain IBD Colon Chips (Fibroblast)

Adj p-val: 0.00039
NES: 1.79

KEGG NOD LIKE RECEPTOR SIGNALING PATHWAY
+Strain vs -Strain IBD Colon Chips (Fibroblast)

Adj p-val: 0.00090
NES: 2.08

REACTOME SIGNALING BY PDGF
+Strain vs -Strain IBD Colon Chips (Fibroblast)

Adj p-val: 0.00428
NES: 2.02

REACTOME DEFECTIVE CFTR CAUSES CYSTIC FIBROSIS
+Strain vs -Strain IBD Colon Chips (Fibroblast)

Adj p-val: 0.03189
NES: 1.82

Genes more highly expressed in fibroblast IBD strain homotypic

Genes more highly expressed in fibroblast IBD no strain homotypic

Extended Data Fig. 9

Extended Data Fig. 10